Kurzfassung

A randomized, double blind phase 3 efficacy and safety study of PF00299804 (Dacomitinib) versus Erlotinib for the treatment of advanced Non-Small Cell Lung Cancer following progression after, or intolerance to, at least one prior Chemotherapy